Larotaxel
| Code | Size | Price |
|---|
| TAR-T15713-25mg | 25mg | £744.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Larotaxel is a taxane analogue with preclinical activity against taxane-resistant breast cancer. It can cross the blood-brain barrier and has a much lower affinity for P-glycoprotein 1. Larotaxel promotes tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis.
CAS:
156294-36-9
Formula:
C45H53NO14
Molecular Weight:
831.912
Purity:
0.98
SMILES:
[H][C@@]12C[C@@H]3C[C@@]33C(=O)[C@]([H])(OC(C)=O)C4=C(C)[C@@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1
References
1. Di?ras V, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul;19(7):1255-60.
2. Morris PG, et al. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85.
3. Zatloukal P, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol. 2008 Aug;3(8):894-901.